Asset profile

Lenacapavir · Sunlenca / Yeztugo

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved — HIV

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2027 (2)
March 2027 (1)
Phase 2HIVRecruiting
Est. primary completion 2027-03 · NCT06749054 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2027 (1)
Phase 2HIVRecruiting
Est. primary completion 2027-08 · NCT07645287 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (2)
January 2028 (1)
Phase 2/3HIVActive not recruiting
Est. primary completion 2028-01 · NCT06544733 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2028 (1)
Phase 3HIVActive not recruiting
Est. primary completion 2028-09 · NCT07047716 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (2)
March 2029 (2)
Phase 3HIVRecruiting
Est. primary completion 2029-03 · NCT07682961 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HIVRecruiting
Est. primary completion 2029-03 · NCT07683000 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (2)
July 2030 (1)
Phase 2/3HIVActive not recruiting
Est. primary completion 2030-07 · NCT06532656 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2030 (1)
Phase 2/3HIVRecruiting
Est. primary completion 2030-10 · NCT07708727 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.